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unitary cost average adjusted by age-gender and Charlson-index
was increased according to CRL category: low: €986.14;
moderate: €1021.20; high: €1107.64 and very high €1328.09;
p < 0.001. These results were obtained in all analysed compo-
nents. Pharmaceutical cost represented 66.2% of the total. CON-
CLUSIONS: Subjects with high CRL showed older age, high
morbidity (diabetes, smoking, hypertension) and CRL presence,
existing gender differences (man) with high consume of sanitary
resources. There are a high margin of improvement in the
primary prevention of health, were should be established cost-
effective measures to promote intervention strategies in this
patients collective.
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OBJECTIVES: The TRITON-TIMI 38 Trial demonstrated that
in patients with acute coronary syndromes (ACS) undergoing
planned percutaneous coronary intervention (PCI), prasugrel
compared to clopidogrel signiﬁcantly reduced the rate of
ischemic events over up to 15 months of follow-up, but
increased the risk of major bleeding. We used patient-level
resource use data to estimate and compare index, follow-up and
total hospitalization costs, exclusive of study drug, for patients
treated with prasugrel vs. clopidogrel in TRITON-TIMI 38,
both in the overall trial population and among selected sub-
groups. METHODS: For the economic study for TRITON,
details regarding hospitalizations for all patients from 8 high
enrolling countries (U.S., Australia, Canada, Germany, Italy,
Spain, U.K., France; n = 3373 prasugrel, 3332 clopidogrel) were
collected prospectively. These data were used to assign DRGs to
all index and subsequent hospitalizations, to which average
2005 Medicare reimbursement rates were applied. Physician
costs associated with all hospitalizations were estimated based
on the DRG-speciﬁc ratio of physician reimbursement to hospi-
tal costs. Estimates of incremental costs associated with PCI-
associated periprocedural MIs and PCI and CABG associated
bleeding events were added separately based on published data
from similar patient populations. RESULTS: For the entire 8
country population, treatment with prasugrel was associated
with a $613 per patient mean reduction in overall hospitaliza-
tion costs, reﬂecting a $7/patient increase in index hospitaliza-
tion costs (components of which included a $38/patient increase
in costs associated with periprocedural bleeds and a $18/patient
decrease in costs resulting from a reduction in periprocedural
MI) and $620/patient reduction in follow-up cost savings due
primarily to prevention of MI and revascularization procedures.
Among the subgroup of patients (n = 5270, 79%) who had no
risk factors for increased bleeding (i.e., prior stroke or TIA, age
>75 yrs, and weight <60 kg), prasugrel was associated with a
$43/patient increase in initial hospital costs ($43/patient increase
due to periprocedural bleed and $21/patient decrease due to
periprocedurlal MI). During followup, costs associated with MI
and repeat revascularizations were $872/patient lower with pra-
sugrel, while costs associated with follow-up bleeding events
were $74/patient higher; aggregate hospitalization costs were
$637/patient lower with prasugrel for this subgroup. Among the
subgroup with 1 or more risk factors for increased bleeding,
initial hospitalization costs were lower by $130 with prasugrel
(despite an average $20 increase in costs due to periprocedural
bleeds), and overall follow-up costs were $395 lower, resulting
in aggregate savings of $525/patient. CONCLUSIONS: For ACS
patients undergoing planned PCI, the lower ischemic event rate
with prasugrel compared to clopidogrel yields a reduction in
overall hospitalization costs, despite increased costs associated
with bleeding. These ﬁndings were accentuated among the large
subgroup of patients with no risk factors for increased bleeding.
These results will have implications for the cost-effectiveness of
alternative antiplatelet strategies for ACS patients undergoing
PCI.
PCV65
COSTS OF BLEEDS ASSOCIATED WITHTREATING ACUTE
CORONARY SYNDROME PATIENTS IN GERMANY
Bufe A1, Briswalter S2, Brown R3
1Universitätsklinik der Universität Witten/Herdecke,Wuppertal,
Wuppertal, Germany, 2GlaxoSmithKline, Munich, Germany, 3United
BioSource Corporation, Bethesda, MD, USA
OBJECTIVES: To estimate the costs to manage bleeds in hospi-
talized acute coronary syndrome (ACS) patients in Germany
treated with antithrombotics, antiplatelet, and ﬁbrinolytic thera-
pies. treated with antithrombotics, antiplatelet, and ﬁbrinolytic
therapies. METHODS: Retrospective hospital chart review of
ACS patients identiﬁed with one of following bleeds: symptom-
atic intracranial haemorrhage (IH), retroperitoneal haemorrhage
(RH), gastrointestinal haemorrhage (GH), decrease in Hb greater
or equal to 3 g/dL (DH), puncture site bleed (PS), or transfusion
of greater than or equal to 2 units of blood product. Reason for
admission, length of stay (LOS), diagnostic procedures, and
transfusion related resources were counted and costed using unit
estimates based upon German DRGs and procedures. Bleed
related LOS was calculated using the reported date of bleed until
discharge. RESULTS: Records of 61 consecutive ACS patients
were included in the study. Average age was 68.6 with 60%
males. Patients were classiﬁed as: 1 IH, 3 RH, 10 GH, 14 DH, 31
PS and 2 with transfusions. The average LOS ranged between 6
and 13.5 days but ranged up to 23 days. The average bleed-
related LOS ranged from 5 to 12 days. Average costs by type
of patient classiﬁcation were: IH €3739, RH €5467, GH €5172,
DH €3336, PS €3380, transfusions €6366. Average cost overall
patients was €3879 of which €3004 occurred after the bleed date.
LOS and resource use details allow hospitals to estimate their
own internal costs of antithrombotics, antiplatelet, and ﬁbrin-
olytic therapies. CONCLUSIONS: German hospitals are paid by
case severity and diagnosis of patients. Understanding the full
costs of managing ACS patients and avoiding bleeds may help
control hospital costs.
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OBJECTIVES: We evaluated the potential costs or cost-savings
of coronary CT angiography (CTA) in a hypothetical patient
population with varying degrees of coronary artery disease
(CAD) prevalence. METHODS: We developed a mathematical
model to evaluate the potential costs associated with coro-
nary CTA after an equivocal or non-diagnostic exercise stress
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